HELPING THE OTHERS REALIZE THE ADVANTAGES OF PANOBINOSTAT

Notwithstanding different setbacks, a number of MDM2 inhibitors have now progressed into late-stage clinical advancement. New procedures have also been produced to reinforce the efficacy of MDM2 inhibitors and also to mitigate their on-focus on toxicity. With this critique, we summarize the development and difficulties in the development of a MDM2